Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919058 | 0.92 | KMT2A (0.56) | KMT2AACHESMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL11919045 | 0.92 | KMT2A (0.56) | KMT2AACHESMN1; SMN2HSD11B1 | |
| SCHEMBL18874058 | 0.91 | KMT2A (0.44) | KMT2AACHESMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL23732169 | 0.90 | KMT2A (0.46) | KMT2AACHESMN1; SMN2HSD11B1TLR7 | |
| SCHEMBL7907323 | 0.90 | KMT2A (0.46) | KMT2AHSD11B1ALOX15TLR7 | |
| SCHEMBL13179268 | 0.89 | KMT2A (0.44) | KMT2AACHESMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL1202619 | 0.89 | KMT2A (0.42) | KMT2AACHESMN1; SMN2HSD11B1KDM4E | |
| SCHEMBL7899320 | 0.88 | HSD11B1 (0.48) | KMT2AHSD11B1ALOX15TLR7 | |
| SCHEMBL13088144 | 0.88 | HSD11B1 (0.48) | KMT2AHSD11B1ALOX15TLR7 | |
| SCHEMBL10281974 | 0.86 | KMT2A (0.47) | KMT2AACHESMN1; SMN2ALDH1A1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023072246-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-04 | — | — | WO | disclosed |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2022266167-A1 | AMIDE AND UREA-CONTAINING TRICYCLIC KRAS INHIBITORS | ERASCA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | HOFFMAN-LA ROCHE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010077663-A2 | SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | KMT2A 736/4885ACHE 4864/4885SMN1; SMN2 4522/4885 |
| US-20230112485-A1 | THERAPEUTIC COMPOUNDS | BRDT, BRPF3, SNRPE | KMT2A 1742/4885ACHE 4710/4885SMN1; SMN2 415/4885 |
| US-20100305084-A1 | BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PI4K2B, PIK3CA, PIK3R2 | KMT2A 4048/4885ACHE 4195/4885SMN1; SMN2 3259/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | KMT2A 3648/4885ACHE 4127/4885SMN1; SMN2 2548/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | KMT2A 40/4885ACHE 4435/4885SMN1; SMN2 1592/4885 |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | KMT2A 4334/4885ACHE 2327/4885SMN1; SMN2 9/4885 |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | KMT2A 2102/4885ACHE 4809/4885SMN1; SMN2 2739/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | KMT2A 3482/4885ACHE 1335/4885SMN1; SMN2 2388/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KMT2A 4343/4885ACHE 4441/4885SMN1; SMN2 2248/4885 |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | KMT2A 1749/4885ACHE 4469/4885SMN1; SMN2 3292/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | KMT2A 2102/4885ACHE 4809/4885SMN1; SMN2 2739/4885 |
| US-20230159545-A1 | ALKYNE-CONTAINING ANTIVIRAL AGENTS | ACE, SARS1, ACE2 | KMT2A 3482/4885ACHE 1335/4885SMN1; SMN2 2388/4885 |
| US-20110207713-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | KMT2A 4144/4885ACHE 3688/4885SMN1; SMN2 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.